Cellular Immunity and DNA Vaccines for the Treatment of HIV / AIDS

Author(s): F. Lori, L. M. Kelly, J. Lisziewicz

Journal Name: Current Medicinal Chemistry - Anti-Infective Agents
Continued as Anti-Infective Agents

Volume 3 , Issue 1 , 2004


Data from the first phase III HIV vaccine trial does not indicate efficacy regarding the production of neutralizing antibodies and prevention of HIV infection. The induction of a potent HIV-specific cellular response through therapeutic vaccination is now thought to be a more attainable goal through HIV DNA vaccines. This review will summarize the immunologic rationale behind the development of vaccines that elicit cellular immune responses, and will then illustrate examples of DNA-based preventive and therapeutic vaccine strategies, which have recently been evaluated in pre-clinical animal studies as well as some human clinical trials; they include: (i) cytokine-augmented DNA vaccines; (ii) CpG enriched plasmid DNAs; (iii) viral vectors and prime-boost strategies; (iv) lipopeptide vaccines; (v) ex vivo dendritic cell-based, and (vii) dendritic cell-targeted vaccines. This set of data will be carefully reviewed in order to understand how this know-how has been or can be used to design meaningful “next-generation” therapeutic vaccines.

Keywords: hiv dna vaccine, cellular immune response, cytokines

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [31 - 41]
Pages: 11
DOI: 10.2174/1568012043354099

Article Metrics

PDF: 8